Kite – a subsidiary of Gilead Sciences ... of relapsed/refractory mantle cell lymphoma (MCL) – becoming the first CAR-T for that use last year – and made sales of $72 million in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback